Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenaya Therapeutics filings document a clinical-stage biotechnology issuer focused on genetic and small-molecule approaches to heart disease. Recent 8-K reports furnish operating results and corporate updates tied to TN-201, TN-401 and TN-301, including clinical and regulatory disclosures for cardiomyopathy programs and research updates for cardiovascular target validation.
The company’s SEC record also includes definitive proxy materials for annual-meeting governance and shareholder voting matters, material-agreement disclosure for its cardiovascular target research collaboration, capital-structure information and Nasdaq continued-listing compliance disclosures. These filings frame Tenaya’s public reporting around pipeline development, financing capacity, governance and common stock status.
Tenaya Therapeutics, Inc. lists Chief Financial Officer Eric J Hyllengren as a reporting person in an initial Form 3 insider ownership report. The structured data show no buy or sell transactions, no derivative positions, and a neutral net buy/sell status at the time of filing.
Tenaya Therapeutics, Inc. granted Chief Financial Officer Eric J. Hyllengren a stock option covering 1,650,000 shares of common stock with an exercise price of 0.8365 per share. The option was issued under the 2024 Inducement Equity Incentive Plan, vests 25% after one year then monthly until fully vested, and expires on July 12, 2036.
Tenaya Therapeutics, Inc. has terminated its lease for the Genetic Medicines Manufacturing Center in Union City, California. The lease covered approximately 94,046 rentable square feet and was originally set to run until July 2031 but will now end on August 31, 2026.
To exit the lease, Tenaya will forfeit a $1,750,000 security deposit and pay a one-time lease termination fee of about $294,200. The facility was decommissioned in 2025 to reduce costs, and existing TN-201 and TN-401 inventory is expected to support ongoing clinical trials.
The company plans to keep its internal process and assay development know-how while transferring its AAV manufacturing process to a contract development manufacturing organization with global capabilities for potential future late-stage development or commercial launch of TN-201 and TN-401.
Tenaya Therapeutics, Inc. has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. He will also serve as Principal Financial Officer and Principal Accounting Officer, overseeing financial strategy, capital allocation, investor relations and corporate development.
Hyllengren brings more than two decades of biotechnology finance and strategy experience, including senior roles at Zura Bio, Atara Biotherapeutics and Amgen, where he executed over $500 million in public financings. His compensation includes a $490,000 base salary, a target bonus equal to 40% of base salary and an option to purchase 1,650,000 shares under Tenaya’s 2024 Inducement Equity Incentive Plan, subject to board approval and time-based vesting.
President and CEO Faraz Ali will cease serving as interim Principal Financial Officer, and Senior Vice President, Finance, Tomohiro (Hiro) Higa will cease serving as acting interim Principal Accounting Officer and retire in the third quarter of 2026, remaining as a consultant to support a smooth transition.
Tenaya Therapeutics director Williams R. Sanders received a grant of stock options for 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were awarded under the company’s 2021 Equity Incentive Plan. They vest in full on May 28, 2027, or earlier if the next annual stockholder meeting occurs before that date, provided Sanders continues as a service provider.
Tenaya Therapeutics director Jeffrey T. Walsh received a stock option grant covering 120,000 shares of common stock at an exercise price of $0.7989 per share. The option was granted under the company’s 2021 Equity Incentive Plan, vests in full on May 28, 2027 (or earlier, before the next annual stockholder meeting), and expires on May 27, 2036. This filing reports an award of options rather than any open-market share purchase or sale.
Tenaya Therapeutics, Inc. director Catherine Stehman-Breen received a grant of stock options covering 120,000 shares of common stock. These options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.
The option grant was made under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan and will vest in full on May 28, 2027, or earlier on the day immediately before the next annual meeting of stockholders after the grant date, if that comes first, provided she continues as a service provider. The options expire on May 27, 2036, and following this grant she holds 120,000 options of this award.
Tenaya Therapeutics director Deepak Srivastava received a grant of stock options for 120,000 shares of common stock at an exercise price of $0.7989 per share. The options vest in full on May 28, 2027, or earlier immediately before the next annual stockholder meeting, if he continues as a service provider. The options expire on May 27, 2036.
Tenaya Therapeutics director Karah Herdman Parschauer received a stock option grant for 120,000 shares of common stock. The option has an exercise price of $0.7989 per share, expires on May 27, 2036, and will vest in full on May 28, 2027 or earlier, the day before the next annual stockholder meeting after the grant, if she continues as a service provider.
Tenaya Therapeutics, Inc. director June Lee received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.
The options will vest in full on May 28, 2027, or earlier on the day immediately before the next annual stockholder meeting after the grant date, as long as Lee continues as a service provider to the company. The options expire on May 27, 2036, and following this grant Lee holds 120,000 options in total.